



IPW

Patent Application
Attorney Docket No. PC25687A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 21st day of July 2004

By _____

Irene Grasham

(Signature of person mailing)

Irene Grasham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Christopher Ian Dallman, et al.

APPLICATION NO.: 10/763,794 : Examiner: To Be Assigned

FILING DATE: January 22, 2004 : Group Art Unit: 1615

TITLE: CRYSTALLINE THERAPEUTIC AGENT : _____

Mail Stop Amendment

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application
Attorney Docket No. PC25687A

A prompt and favorable response is earnestly solicited.

Date: July 21, 2009
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811



PATENT INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC25687A			SERIAL NO. 10/763,794					
			APPLICANT Christopher Ian Dallman, et al.								
			FILING DATE 01/22/2004			GROUP 1615					
U.S. PATENT DOCUMENTS											
EXAMINER INITIAL	DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS											
DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
									YES	NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
			Admour, et al., "Solid Modifications in Sildenafil Citrate", <u>3rd World Meeting on Pharmaceutics, Biopharmaceutics, and Pharmaceutical Technology, Berlin, pp. 639,640, (3-6 April 2000)</u>								
EXAMINER			DATE CONSIDERED								
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>											